Now why was learning all this useful when it comes to autoimmune diseases?
Well, here’s why:
Immune system balance.
The kynurenine pathway (KP) acts as a natural “brake” on overactive immunity, functioning as one of the body’s key mechanisms for maintaining immune homeostasis and promoting tolerance during inflammation, infection and so on.
This suppressive effect occurs through two interconnected mechanisms:
Tryptophan depletion (starvation strategy):
By rapidly breaking down tryptophan via IDO1 (in immune cells like dendritic cells, macrophages, and endothelial cells) or TDO (systemically), the pathway creates a local tryptophan-depleted microenvironment at sites of inflammation or immune activation.
Effector T cells (especially CD4 and CD8 subsets) are highly dependent on extracellular tryptophan for proliferation, activation, and overall function (they require it to charge tRNAs and sustain protein synthesis during rapid division).
When Trp levels drop, uncharged tRNAs accumulate, activating the GCN2 kinase (general control nonderepressible 2, an amino acid starvation sensor).
GCN2 phosphorylates eIF2α, triggering an integrated stress response that halts cell cycle progression (arrest at mid-G1), induces T-cell anergy (unresponsiveness), sensitizes cells to apoptosis, and inhibits mTORC1 signaling.
This selectively suppresses pro-inflammatory effector responses (Th1 cells producing IFN-γ, Th17 cells producing IL-17) while sparing or even favoring slower-dividing or metabolically adapted cells like regulatory T cells (Tregs).
Production of bioactive kynurenine metabolites (signaling strategy):
The primary product, kynurenine (KYN), acts as an endogenous ligand for the aryl hydrocarbon receptor (AhR), a transcription factor expressed in immune cells (T cells, dendritic cells, macrophages, etc.).
KYN-AhR binding drives AhR activation, which:
Promotes differentiation of naïve CD4 T cells into FoxP3 regulatory T cells (Tregs).
Inhibits RORγt (transcription factor for Th17 cells), reducing Th17 differentiation and IL-17 production.
Suppresses Th1 responses.
Induces tolerogenic dendritic cells (DCs) that further reinforce Treg expansion and suppress effector T/B cell activity.
Other metabolites such as kynurenic acid or 3-hydroxyanthranilic acid contribute to anti-inflammatory effects, such as inhibiting pro-inflammatory cytokine release or modulating AhR-independent pathways.
In healthy states, this creates a negative feedback loop: inflammation (via IFN-γ/TNF-α) activates IDO1 → KP ramps up → Trp depletion KYN/AhR signaling → effector suppression Treg promotion → resolution of inflammation and restoration of tolerance.
Inflammation control.
During acute threats (such as infection, injury, trauma, or short-term immune activation), the kynurenine pathway helps dial down the immune response once the danger has passed, contributing to the timely resolution of inflammation and preventing unnecessary tissue damage.
In these scenarios:
Pro-inflammatory cytokines (especially IFN-γ from activated Th1 cells, but also TNF-α and IL-6) transiently upregulate IDO1 in immune cells (dendritic cells, macrophages, endothelial cells) and inflamed tissues.
This ramps up KP activity: tryptophan depletion starves rapidly proliferating effector T cells (via GCN2 activation and integrated stress response), while kynurenine and downstream metabolites (particularly kynurenic acid/KYNA and some 3-hydroxyanthranilic acid) promote anti-inflammatory effects.
The result is a negative feedback loop: inflammation triggers KP → KP suppresses excessive effectors and boosts Tregs → inflammation resolves → KP activity returns to baseline.
This “resolution-promoting” role is evolutionarily adaptive—it allows the immune system to mount a strong but controlled response, clear the threat, and restore homeostasis without chronic collateral damage.
But in chronic states (persistent low-grade inflammation, unresolved infections, autoimmunity, aging-related “inflammaging,” stress, or post-viral syndromes like long COVID), overactivation of the KP can backfire, sustaining or even amplifying low-grade inflammation and shifting toward harmful metabolites.
Key ways this happens:
Persistent cytokine drive (chronic IFN-γ, TNF-α, IL-6 from ongoing immune activation, viral remnants, autoantigens, or microbiome dysbiosis) keeps IDO1 and sometimes KMO overexpressed.
This leads to prolonged tryptophan depletion → ongoing suppression of effector T cells, but if Tregs become dysfunctional or overwhelmed, tolerance fails, allowing autoreactive responses to persist.
Metabolic skewing: Flux diverts toward the neurotoxic/pro-inflammatory branch (3-hydroxykynurenine/3-HK, quinolinic acid/QUIN) due to upregulated KMO in microglia/macrophages → increased oxidative stress, excitotoxicity (QUIN overstimulates NMDA receptors), mitochondrial dysfunction, and further cytokine release → vicious cycle of unresolved inflammation.
Failed resolution: Instead of turning off, the pathway contributes to sustained low-grade systemic inflammation (”metaflammation”), neuroinflammation (brain fog, fatigue), tissue damage (neurodegeneration in MS models, joint erosion in RA), and impaired energy metabolism (disrupted NAD homeostasis).
For example, in long COVID and ME/CFS-like states, studies show exaggerated KP activation post-acute phase, with elevated KYN/Trp ratios and metabolite imbalances correlating with persistent fatigue, cognitive issues, and immune dysregulation.
Brain and nervous system function.
Several kynurenine pathway metabolites are small, lipophilic molecules that readily cross the blood-brain barrier (BBB) either passively due to their size/chemistry or via specific transporters.
Once in the central nervous system (CNS), they directly influence neurotransmission, neuronal excitability, glial function, and overall brain homeostasis.
This makes the KP one of the key metabolic links between peripheral inflammation/immune activation and CNS effects (often called the “immune-to-brain axis”).
The two main opposing branches produce metabolites with dramatically different effects on the brain:
Kynurenic acid (KYNA)
Produced mainly by astrocytes (via kynurenine aminotransferases/KATs, especially KAT II).
Acts as a broad-spectrum endogenous antagonist at ionotropic glutamate receptors:
Strongest at the glycine co-agonist site of NMDA receptors → reduces excessive glutamate signaling and prevents excitotoxicity (overactivation leading to calcium overload, mitochondrial damage, oxidative stress, and neuronal death).
Also blocks AMPA and kainate receptors to a lesser extent.
Inhibits α7 nicotinic acetylcholine receptors (α7 nAChRs) on presynaptic terminals and microglia → modulates acetylcholine release, dopamine signaling, and microglial activation.
Activates the aryl hydrocarbon receptor (AhR) in CNS cells → promotes anti-inflammatory and neuroprotective gene expression.
Quinolinic acid (QUIN)
Produced primarily by activated microglia and infiltrating macrophages (via kynurenine 3-monooxygenase/KMO and downstream enzymes).
Functions as a potent, selective agonist at NMDA receptors (especially extrasynaptic NMDA receptors containing NR2B subunits) → causes prolonged calcium influx, activation of nitric oxide synthase, free radical generation, lipid peroxidation, and mitochondrial dysfunction.
Promotes oxidative stress and energy failure in neurons and oligodendrocytes.
Stimulates microglial activation and release of pro-inflammatory cytokines (TNF-α, IL-1β), creating a feed-forward loop of neuroinflammation.
Can induce apoptosis or necrosis in vulnerable neurons in the hippocampus for example.
This is why low KYNA and/or high QUIN/KYN ratios are implicated in many psychiatric diseases.
And these are just a few of the reasons.